BioRestorative to sell 1,834,862 shares, 2,752,293 warrants to public

Aegis assists; warrants exercisable at 125% and 115% of share price

By Devika Patel

Knoxville, Tenn., Oct. 16 – BioRestorative Therapies, Inc. will sell 1,834,862 common shares, 1,834,862 class A warrants and 917,431 class B warrants in its public offering with a 45-day greenshoe of 275,229 additional shares, 275,229 additional class A warrants and 137,615 additional class B warrants, according to an S-1/A filed Friday with the Securities and Exchange Commission. The deal was announced on June 3.

The five-year class A warrants will be exercisable at 125% of the per-share price. The 18-month class B warrants will be exercisable at 115% of the per-share price.

Aegis Capital Corp. is the bookrunning manager.

Proceeds will be used to submit an IND application for brtxDISC to the Federal Drug Administration, for research and development and for general corporate and working capital purposes.

Based in Jupiter, Fla., BioRestorative is a life sciences company focused on cellular therapies for various personal medical applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.